KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Cash: 2014-2024

Historic Change in Cash for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to -$91.3 million.

  • CRISPR Therapeutics AG's Change in Cash rose 135.89% to $92.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.8 million, marking a year-over-year increase of 120.11%. This contributed to the annual value of -$91.3 million for FY2024, which is 151.57% down from last year.
  • CRISPR Therapeutics AG's Change in Cash amounted to -$91.3 million in FY2024, which was down 151.57% from $177.0 million recorded in FY2023.
  • In the past 5 years, CRISPR Therapeutics AG's Change in Cash ranged from a high of $236.7 million in FY2020 and a low of -$715.9 million during FY2022.
  • Over the past 3 years, CRISPR Therapeutics AG's median Change in Cash value was -$91.3 million (recorded in 2024), while the average stood at -$210.1 million.
  • In the last 5 years, CRISPR Therapeutics AG's Change in Cash plummeted by 203.75% in 2021 and then soared by 124.73% in 2023.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's Change in Cash stood at $236.7 million in 2020, then slumped by 203.75% to -$245.5 million in 2021, then plummeted by 191.57% to -$715.9 million in 2022, then spiked by 124.73% to $177.0 million in 2023, then plummeted by 151.57% to -$91.3 million in 2024.